Esther García Gil

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

Paul Jones, Dave Singh, Eric Bateman et al. · European Respiratory Journal · 2012 · 182 citations

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Dave Singh, Paul Jones, Eric Bateman et al. · BMC Pulmonary Medicine · 2014 · 172 citations · Full text

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 168 citations · Full text

Asthma, Severe Eosinophilic Asthma, Allergy +10

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies‐Gow, Mark Gurnell, Liam G. Heaney et al. · The Lancet Respiratory Medicine · 2021 · 165 citations

Asthma, Allergy, Personalised Reduction Algorithm +9

Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD

Henry Chrystyn, Mark Small, Gary Milligan et al. · Respiratory Medicine · 2013 · 145 citations

Pulmonary Care, Health Policy, Advanced Lung Disease +8